At 11.4% CAGR, Middle East & Africa Vaccine Adjuvants Market is Projected to be Worth US$ 187.15 Million by 2030, says Business Market Insights

According to Business Market Insights’ research, the Middle East & Africa vaccine adjuvants market was valued at US$ 78.94 million in 2022 and is expected to reach US$ 187.15 million by 2030, registering a CAGR of 11.4% from 2022 to 2030. Approvals of veterinary vaccine adjuvants and rising number of infectious disease outbreaks and pandemic are among the critical factors attributed to drive the Middle East & Africa vaccine adjuvants market growth.

According to the World Bank 2023 report, bacterial, viral, parasite, or fungal diseases can be contagious, spreading directly from person to person or animal to person. As of June 2024, tens of thousands of individuals in the Democratic Republic of the Congo (DRC) were infected by the largest known outbreak of the viral mpox disease. The government proclaimed it to be an epidemic in December 2022. The disease, once known as "monkeypox," is brought on by the monkeypox virus and is usually zoonotic, indicating it can spread from animals to people. From the start of 2022, eight endemic Member States of the Africa Union (AU) have reported 1,267 confirmed cases and 226 deaths from mpox across the continent. Therefore, the emergence of various infectious diseases with the associated cost burden accelerates the manufacturers' demand for vaccines and vaccine adjuvants.

On the flip side, product recalls and adverse effects hamper the growth of Middle East & Africa vaccine adjuvants market.

Based adjuvant class, the Middle East & Africa vaccine adjuvants market is segmented into mineral salt adjuvant, emulsion adjuvant, liposome adjuvant, and others. The mineral salt adjuvant segment held 39.7% share of Middle East & Africa vaccine adjuvants market share in 2022, amassing US$ 31.31 million. It is projected to garner US$ 70.79 million by 2030 to register 10.7% CAGR during 2022–2030.

By type, the Middle East & Africa vaccine adjuvants market is bifurcated into human vaccine adjuvant and veterinary vaccine adjuvant. The human vaccine adjuvant segment held 62.3% share of Middle East & Africa vaccine adjuvants market in 2022, amassing US$ 49.18 million. It is anticipated to garner US$ 119.37 million by 2030 to expand at 11.7% CAGR during 2022–2030.

By country, the Middle East & Africa vaccine adjuvants market is segmented into Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa. Saudi Arabia segment held 30.4% share of Middle East & Africa vaccine adjuvants market in 2022, amassing US$ 23.96 million. It is anticipated to garner US$ 60.24 million by 2030 to expand at 12.2% CAGR during 2022–2030

Key players operating in the Middle East & Africa vaccine adjuvants market are Croda International Plc; CSL Ltd; GSK Plc; Novavax Inc; and Phibro Animal Health Corp, among others.

• October, 2023; GSK plc announced results from its phase III trial [NCT05590403] evaluating the immune response and safety of Arexvy (respiratory syncytial virus vaccine, adjuvanted) in adults aged 50 to 59, including those at increased risk of respiratory syncytial virus lower respiratory tract disease due to certain underlying medical conditions. On October 25, 2023, the findings were given to the Advisory Committee on Immunization Practices of the US Centers for Disease Control and Prevention.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com